KR101689803B1 - Composition for preventing or treating of diabetes or obesity containing Apelin-16 - Google Patents
Composition for preventing or treating of diabetes or obesity containing Apelin-16 Download PDFInfo
- Publication number
- KR101689803B1 KR101689803B1 KR1020150161139A KR20150161139A KR101689803B1 KR 101689803 B1 KR101689803 B1 KR 101689803B1 KR 1020150161139 A KR1020150161139 A KR 1020150161139A KR 20150161139 A KR20150161139 A KR 20150161139A KR 101689803 B1 KR101689803 B1 KR 101689803B1
- Authority
- KR
- South Korea
- Prior art keywords
- apelin
- diabetes
- composition
- obesity
- glucose
- Prior art date
Links
- 108010061485 apelin-16 Proteins 0.000 title claims abstract description 60
- 206010012601 diabetes mellitus Diseases 0.000 title claims abstract description 30
- 208000008589 Obesity Diseases 0.000 title claims abstract description 23
- 235000020824 obesity Nutrition 0.000 title claims abstract description 23
- 239000000203 mixture Substances 0.000 title claims abstract description 21
- 230000003914 insulin secretion Effects 0.000 claims abstract description 34
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims abstract description 20
- 208000002249 Diabetes Complications Diseases 0.000 claims abstract description 14
- 206010012655 Diabetic complications Diseases 0.000 claims abstract description 14
- 239000008280 blood Substances 0.000 claims abstract description 13
- 210000004369 blood Anatomy 0.000 claims abstract description 13
- 238000009825 accumulation Methods 0.000 claims abstract description 11
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims abstract description 10
- 239000004480 active ingredient Substances 0.000 claims abstract description 9
- 208000004930 Fatty Liver Diseases 0.000 claims abstract description 6
- 206010019708 Hepatic steatosis Diseases 0.000 claims abstract description 6
- 208000010706 fatty liver disease Diseases 0.000 claims abstract description 6
- 231100000240 steatosis hepatitis Toxicity 0.000 claims abstract description 6
- 235000013305 food Nutrition 0.000 claims description 13
- 235000012000 cholesterol Nutrition 0.000 claims description 8
- 201000010099 disease Diseases 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 6
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims description 5
- 208000033679 diabetic kidney disease Diseases 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 206010003210 Arteriosclerosis Diseases 0.000 claims description 4
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 4
- 208000011775 arteriosclerosis disease Diseases 0.000 claims description 4
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 3
- 208000031226 Hyperlipidaemia Diseases 0.000 claims description 3
- 206010020772 Hypertension Diseases 0.000 claims description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract description 50
- 239000008103 glucose Substances 0.000 abstract description 46
- QZNKGTRFBWGADN-SLUWFFAESA-N apelin-12 Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@@H](CCSC)C(=O)N3CCC[C@H]3C(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCC(=O)N)N QZNKGTRFBWGADN-SLUWFFAESA-N 0.000 abstract description 24
- 108010006026 apelin-12 peptide Proteins 0.000 abstract description 24
- 101800001808 Apelin-36 Proteins 0.000 abstract description 22
- 102400000251 Apelin-36 Human genes 0.000 abstract description 19
- BVTLGARMSLXAHI-VDEROMQGSA-N apelin-36 Chemical compound C([C@@H](C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CCSC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)CNC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(C)C)C(C)C)C1=CN=CN1 BVTLGARMSLXAHI-VDEROMQGSA-N 0.000 abstract description 19
- 230000000694 effects Effects 0.000 abstract description 13
- 210000003734 kidney Anatomy 0.000 abstract description 7
- 239000003814 drug Substances 0.000 abstract description 6
- 230000002195 synergetic effect Effects 0.000 abstract description 5
- 229940124597 therapeutic agent Drugs 0.000 abstract description 3
- 230000003178 anti-diabetic effect Effects 0.000 abstract description 2
- 230000003579 anti-obesity Effects 0.000 abstract description 2
- 239000003472 antidiabetic agent Substances 0.000 abstract description 2
- 230000005764 inhibitory process Effects 0.000 abstract description 2
- 230000029537 positive regulation of insulin secretion Effects 0.000 abstract description 2
- 230000003449 preventive effect Effects 0.000 abstract description 2
- 230000009467 reduction Effects 0.000 abstract description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 44
- 102000004877 Insulin Human genes 0.000 description 22
- 108090001061 Insulin Proteins 0.000 description 22
- 229940125396 insulin Drugs 0.000 description 22
- 108010052412 Apelin Proteins 0.000 description 20
- 102000018746 Apelin Human genes 0.000 description 19
- BWVPHIKGXQBZPV-QKFDDRBGSA-N apelin Chemical compound NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)N1[C@H](C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=2NC=NC=2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=2NC=NC=2)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CCSC)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(O)=O)CCC1 BWVPHIKGXQBZPV-QKFDDRBGSA-N 0.000 description 18
- 235000009200 high fat diet Nutrition 0.000 description 16
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 13
- 241000699666 Mus <mouse, genus> Species 0.000 description 12
- 239000003925 fat Substances 0.000 description 9
- 230000001965 increasing effect Effects 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 8
- 230000035508 accumulation Effects 0.000 description 8
- 235000019197 fats Nutrition 0.000 description 8
- 150000001413 amino acids Chemical class 0.000 description 7
- 238000000034 method Methods 0.000 description 6
- 239000013642 negative control Substances 0.000 description 6
- 210000000496 pancreas Anatomy 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 239000013641 positive control Substances 0.000 description 6
- 235000000346 sugar Nutrition 0.000 description 6
- 102400000322 Glucagon-like peptide 1 Human genes 0.000 description 5
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 239000012981 Hank's balanced salt solution Substances 0.000 description 4
- 239000012980 RPMI-1640 medium Substances 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 235000013376 functional food Nutrition 0.000 description 4
- 238000003018 immunoassay Methods 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 235000012149 noodles Nutrition 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 235000021067 refined food Nutrition 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 210000002700 urine Anatomy 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 108010088751 Albumins Proteins 0.000 description 3
- 102000009027 Albumins Human genes 0.000 description 3
- 108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 description 3
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 description 3
- 108010004460 Gastric Inhibitory Polypeptide Proteins 0.000 description 3
- 102100039994 Gastric inhibitory polypeptide Human genes 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- HSRJKNPTNIJEKV-UHFFFAOYSA-N Guaifenesin Chemical compound COC1=CC=CC=C1OCC(O)CO HSRJKNPTNIJEKV-UHFFFAOYSA-N 0.000 description 3
- 101000886868 Homo sapiens Gastric inhibitory polypeptide Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 238000009534 blood test Methods 0.000 description 3
- 229940090124 dipeptidyl peptidase 4 (dpp-4) inhibitors for blood glucose lowering Drugs 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 229960002146 guaifenesin Drugs 0.000 description 3
- 235000013402 health food Nutrition 0.000 description 3
- 230000003345 hyperglycaemic effect Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 230000003248 secreting effect Effects 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 102000029816 Collagenase Human genes 0.000 description 2
- 108060005980 Collagenase Proteins 0.000 description 2
- 239000004278 EU approved seasoning Substances 0.000 description 2
- 101800000224 Glucagon-like peptide 1 Proteins 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 2
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 235000008429 bread Nutrition 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 229960002424 collagenase Drugs 0.000 description 2
- 210000001953 common bile duct Anatomy 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 235000021186 dishes Nutrition 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 201000010063 epididymitis Diseases 0.000 description 2
- 235000013373 food additive Nutrition 0.000 description 2
- 239000002778 food additive Substances 0.000 description 2
- 235000011194 food seasoning agent Nutrition 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 238000001794 hormone therapy Methods 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 235000013372 meat Nutrition 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- -1 olive oil Chemical compound 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 201000001474 proteinuria Diseases 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 230000004584 weight gain Effects 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- CONKBQPVFMXDOV-QHCPKHFHSA-N 6-[(5S)-5-[[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]methyl]-2-oxo-1,3-oxazolidin-3-yl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C[C@H]1CN(C(O1)=O)C1=CC2=C(NC(O2)=O)C=C1 CONKBQPVFMXDOV-QHCPKHFHSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 108091008803 APLNR Proteins 0.000 description 1
- 208000004611 Abdominal Obesity Diseases 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 102400000252 Apelin-13 Human genes 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 206010065941 Central obesity Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 108010082495 Dietary Plant Proteins Proteins 0.000 description 1
- 101100300807 Drosophila melanogaster spn-A gene Proteins 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 102000018711 Facilitative Glucose Transport Proteins Human genes 0.000 description 1
- 240000008620 Fagopyrum esculentum Species 0.000 description 1
- 235000009419 Fagopyrum esculentum Nutrition 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- 102000051325 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- 108091052347 Glucose transporter family Proteins 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 101000771523 Homo sapiens Apelin Proteins 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 102000003746 Insulin Receptor Human genes 0.000 description 1
- 108010001127 Insulin Receptor Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- 108091007960 PI3Ks Proteins 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 108010026552 Proteome Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- XXCCRHIAIBQDPX-PEWBXTNBSA-N apelin-13 Chemical compound C([C@@H](C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CCSC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)CCC(N)=O)C1=CN=CN1 XXCCRHIAIBQDPX-PEWBXTNBSA-N 0.000 description 1
- 108010040480 apelin-13 peptide Proteins 0.000 description 1
- SVWSKJCJNAIKNH-MJZUAXFLSA-N apelin-17 Chemical compound C([C@@H](C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CCSC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](N)CCCCN)C1=CN=CN1 SVWSKJCJNAIKNH-MJZUAXFLSA-N 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 235000013574 canned fruits Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000000779 depleting effect Effects 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000006274 endogenous ligand Substances 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 210000000918 epididymis Anatomy 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000019688 fish Nutrition 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 235000013611 frozen food Nutrition 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 230000030136 gastric emptying Effects 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 102000048606 human APLN Human genes 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000002350 laparotomy Methods 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 230000006372 lipid accumulation Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 235000013310 margarine Nutrition 0.000 description 1
- 239000003264 margarine Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 210000005084 renal tissue Anatomy 0.000 description 1
- 230000029054 response to nutrient Effects 0.000 description 1
- 230000036186 satiety Effects 0.000 description 1
- 235000019627 satiety Nutrition 0.000 description 1
- 235000015067 sauces Nutrition 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 235000013555 soy sauce Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 235000019871 vegetable fat Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 238000004260 weight control Methods 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/328—Foods, ingredients or supplements having a functional effect on health having effect on glycaemic control and diabetes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/332—Promoters of weight control and weight loss
Abstract
The present invention relates to a composition for preventing or treating diabetes or obesity comprising apelin-12, apelin-16 or apelin-36 as an active ingredient And more particularly to a composition containing apelin-12, apelin-16 or apelin-36, which further promotes insulin secretion by high glucose concentration and exhibits a synergistic effect, The present invention relates to a composition for preventing or treating diabetes or obesity. The apelin-12, apelin-16 or apelin-36 according to the present invention, through the stimulation of insulin secretion, results in a reduction in blood cholesterol, triglyceride levels and blood glucose In addition, it exhibits excellent antidiabetic and anti-obesity effects such as fat accumulation, inhibition of fatty liver and kidney damage, and thus is very useful as a preventive or therapeutic agent for diabetes, diabetic complication or obesity.
Description
The present invention relates to a composition for preventing or treating diabetes or obesity comprising apelin-12, apelin-16 or apelin-36 as an active ingredient And more particularly to a composition containing apelin-12, apelin-16 or apelin-36, which further promotes insulin secretion by high glucose concentration and exhibits a synergistic effect, The present invention relates to a composition for preventing or treating diabetes or obesity.
Incretin hormone is a hormone secreted from the small intestine by ingesting food, helping to secrete insulin from the pancreas and is recently seen as a new alternative to diabetes treatment. The most important advantages of treatment with incretin hormone are that it has few side effects such as hypoglycemia and weight gain, which are the blind points of insulin hormone therapy, and also beta cell of pancreas damaged by diabetes is regenerated, to be. Glucagon-like peptide-1 (GLP-1) and glucose dependent insulinotropic polypeptide (GIP) are known to be produced and secreted in the intestine in response to nutrients. GLP-1 and GIP are glucose-dependent methods that lower blood glucose levels through increased insulin secretion and decreased secretion of glucagon, delay gastric emptying rate, increase satiety and thus not affect weight gain Lt; / RTI > However, since both hormones are rapidly degraded by dipeptidyl peptidase-4 (DPP-4), they are difficult to use for therapeutic purposes.
To overcome this problem, GLP-1 analogs that have not been degraded by DPP-4 inhibitors or DPP-4 have been developed. The DPP-4 inhibitor is known to inhibit the degradation of active GLP-1 by nutrients, improving HbA1c by up to 0.7%, and the GLP-1 analogue by up to 1% in HbA1c. However, the presently used GLP-1 analogue or DPP-4 inhibitor has been reported to have low efficacy or risk of pancreatitis or pancreatic cancer, and thus a new therapeutic agent for diabetes needs to be developed.
It is known that Akt, AS (Akt substrate) 160, PKCzeta, etc. are mainly involved in the regulation of glucose control and act mainly on the transport of glucose transporter protein. In addition, the pathogenesis at the molecular level for glucose, sugar, and urine is considered to be the cause of the disease rather than the defect of the insulin receptor itself, since the signal transduction between proteins through the receptor-mediated process, especially the PI-3 kinase (phosphoinositide-3 kinase) have. Therefore, since the therapeutic effect of insulin on diabetes is limited, it is important to discover new target proteins and their molecular mechanisms related to glucose control.
Accordingly, the present inventors have made intensive efforts to develop
It is an object of the present invention to provide a method for the treatment of diabetes mellitus comprising diabetes mellitus comprising apelin-12, apelin-16 or apelin-36 which can regulate blood glucose by promoting insulin secretion, And to provide a pharmaceutical composition and food for preventing or treating complications or obesity.
The present invention relates to a pharmaceutical composition for preventing or treating diabetes, diabetic complications or obesity comprising apelin-12, apelin-16 or apelin-36 as an active ingredient. Lt; / RTI >
The present invention also relates to a method for the prevention or amelioration of diabetes, diabetic complications or obesity comprising as an active ingredient apelin-12, apelin-16 or apelin-36 Food.
The apelin-12, apelin-16 or apelin-36 according to the present invention, through the stimulation of insulin secretion, results in a reduction in blood cholesterol, triglyceride levels and blood glucose In addition, it exhibits excellent antidiabetic and anti-obesity effects such as fat accumulation, inhibition of fatty liver and kidney damage, and thus is very useful as a preventive or therapeutic agent for diabetes, diabetic complication or obesity.
1 is a graph showing the amount of insulin after administration of apelin-16 to pancreatic beta cell line (INS-1).
Figure 2 shows the amount of insulin measured after treatment with apellin-16 in islets isolated from animals.
FIG. 3 shows the effect of increasing apelin-16 induced insulin secretion under high glucose (25 mM glucose) conditions.
FIG. 4 shows the observation of fat accumulation in the abdomen, epididymis, liver, and kidney after administering Apelin-16 to a mouse model of high fat diet.
FIG. 5 is a graph showing the levels of proteinuria after administering apelin-16 to a mouse model in which obesity was induced by high fat diet.
FIG. 6 shows the measurement of insulin levels after administering various types of apelin (36, 16, 12) to the pancreatic beta cell line (INS-1).
FIG. 7 shows the treatment of various types of apellins (36, 16, 12) in islets isolated from animals and then measuring the amount of insulin.
Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. In general, the nomenclature used herein is well known and commonly used in the art.
Apelin (APLN) is a human APLN Is an endogenous ligand for the G-protein-coupled APJ receptor (Lee et al., J. Neurochem . , Vol . 251 (2): 471-6, 1988) as a peptide encoded by a gene (Tatemoto K et al . Kleinz et al., Pharmacol . Ther . 107 (2): 198-211, 2005, pp . 74 (1): 34-41, 2000; Szokodi et al., Circ . ). The apelin gene encodes a 77 amino acid preproprotein with a signal peptide at the N-terminal site. After the signal peptide is cleaved and translocated to the endoplasmic reticulum, the 55 amino acid proprotein apelin produces several active fragments, the 36 amino acid peptides corresponding to SEQ ID NOS: 42-77 are Apelin-36, The 17 amino acid peptides corresponding to 77 were named Apelin-17 and the 13 amino acid peptides corresponding to SEQ ID NOS: 65-77 were named Apelin-13. Recently, 46 different apelin peptides from Apelin-55 (proaphelin) to Apelin-12 have been identified (Mesmin C et al., J Proteome Res 10 (11): 5222-31, 2011)
Apelin / APJ pathway is widely expressed in cardiovascular and apelinin has beneficial cardiovascular effects in preclinical models. Administration of acute apelin in humans causes peripheral and coronary vasodilation and increases cardiac output. APJ efficacy is emerging as a therapeutic target for patients with heart failure.
Apelin has also been identified as one of the new myokine proteins (A Basse-Patin et al., Int J Obes . 38 (5): 707-13, 2014). Myocaine is an active substance expressed or synthesized and secreted from skeletal muscle by physical activity , i.e., exercise (Pedersen et al., Journal of Applied Physiology, 103 (3): 1093-98, 2007). IL-6 is known as a representative mycaine, and this myocaine improves immunity, prevents weight control and arteriosclerosis. Therefore, it can be understood that the effect of preventing diabetes or obesity by exercise is due to the secretion of myocaine such as apelin.
In the present invention, islets isolated from the pancreatic beta cell line and mouse were treated with apelin-12, -16, -36, or apelin-12, -16, and -36 under high glucose conditions to confirm insulin secretion promotion. In addition, by confirming the effect of inhibiting lipid accumulation and renal damage, it was confirmed that apelin-12, -16, and -36 were effective for treating or preventing diabetes, obesity or kidney damage.
Accordingly, the present invention relates to a pharmaceutical composition comprising diabetes mellitus, diabetic complications or obesity, which comprises, as an active ingredient, apelin-12, apelin-16 or apelin- And to a pharmaceutical composition for preventing or treating such diseases.
In the present invention, the diabetes mellitus may be a
In the present invention, the apelin-12, apelin-16 or apelin-36 may be characterized as promoting insulin secretion. Preferably, the apelin- May be characterized by having a synergistic effect for further promoting insulin secretion by the high-concentration saccharide.
In the present invention, the above-mentioned apelin-12, apelin-16 or apelin-36 may be characterized by decreasing total cholesterol or triglyceride in blood And further, the fat accumulation can be suppressed.
In the present invention, the above-mentioned apelin-12, apelin-16 or apelin-36 may be characterized by inhibiting blood glucose due to an increase in insulin secretion And is also characterized by preventing renal toxicity caused by hyperglycemia.
The composition containing apelin-12, apelin-16 or apelin-36 of the present invention can be prepared by adding appropriate carriers, excipients or diluents according to conventional methods . Examples of carriers, excipients and diluents that can be included in the composition include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, specialty, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, Cellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil.
The composition containing apelin-12, apelin-16 or apelin-36 of the present invention may be formulated into a powder, granule, capsule, , A suspension, a solution, an emulsion, a syrup, a sterilized aqueous solution, a non-aqueous solution, a suspension, a freeze-drying agent, and a suppository.
In the case of formulation, a diluent or excipient such as a filler, a weighting agent, a binder, a wetting agent, a disintegrant, a surfactant, and the like is usually used. Solid formulations for oral administration include tablets, pills, powders, granules, capsules and the like, which may contain at least one excipient such as starch, calcium carbonate, sucrose, sucrose), lactose, gelatin, and the like. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used. Examples of the liquid preparation for oral use include suspensions, solutions, emulsions, and syrups. In addition to water and liquid paraffin, simple diluents commonly used, various excipients such as wetting agents, sweeteners, fragrances, preservatives and the like may be included . Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, freeze-dried preparations, and suppositories. Examples of the suspending agent include propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like. As the base of the suppository, witepsol, macrogol, tween 60, cacao paper, laurin, glycerol gelatin and the like can be used.
The preferred dosage of the present invention varies depending on the condition and the weight of the patient, the degree of disease, the drug form, the administration route and the period, but can be appropriately selected by those skilled in the art. However, for the desired effect, the compound of the present invention is preferably administered at a daily dose of 0.001 to 100 mg / kg, preferably 0.01 to 10 mg / kg. The administration may be carried out once a day, or in several divided doses orally. The dose is not intended to limit the scope of the invention in any way.
The composition of the present invention can be used alone or in combination with methods for the prevention or treatment of diabetes, diabetic complication or obesity, or using surgery, radiation therapy, hormone therapy, chemotherapy and biological response modifiers.
In another aspect, the present invention provides a method of preventing diabetes, diabetic complications or obesity comprising as an active ingredient apelin-12, apelin-16 or apelin-36 Or improving food.
The food of the present invention can be manufactured in all forms such as functional food, nutritional supplement, health food and food additives. For example, as a health food, Rad51 of the present invention can be prepared in the form of tea, juice, and drink for drinking, granulated, encapsulated, and powdered. Functional foods also include beverages (including alcoholic beverages), fruits and processed foods (such as canned fruits, bottled, jam, marmalade, etc.), fish, meat and processed foods such as ham, sausages, , Breads and noodles (eg udon, buckwheat noodles, ramen noodles, spaghetti, macaroni, etc.), fruit juice, various drinks, cookies, sugar, dairy products such as butter, chitzs, edible vegetable fats, margarine, vegetable protein, , Frozen foods, various kinds of seasonings (for example, soybean paste, soy sauce, sauce, etc.) by adding the apelin of the present invention.
The health functional food also includes various forms of functional food, nutritional supplement, health food, food additive and the like as a food composition, and it can be prepared in various forms according to a conventional method known in the art, for example, 12, apelin-16, or apelin-36 in the form of tea, juice, or drink, granulating, encapsulating, And adding the extract to various foods such as beverage, fruit and processed food, fish oil, meat and processed foods thereof, breads, noodles, seasonings, and the like.
[Example]
Hereinafter, the present invention will be described in more detail with reference to Examples. It is to be understood by those skilled in the art that these embodiments are merely illustrative of the present invention and that the scope of the present invention is not construed as being limited by these embodiments.
Example One: Apelin -16 Insulin secretion measurement
In this Example, in order to confirm increase of insulin secretion by apelin-16, islets isolated from pancreatic beta cell line (INS-1) (ATCC, American type culture collection) -16, and the amount of insulin was measured.
1-1: Insulin secretion in pancreatic beta cell line (INS-1)
2 x 10 6 pancreatic beta cell lines (INS-1) were inoculated into 6-well plates and cultured in RPMI 1640 medium containing 6 mM glucose for 3 days. The cultured pancreatic beta cell line (INS-1) was washed twice with glucose-free KRBS buffer, and 2.5 mM glucose (negative control), 25 mM glucose (positive control) and 10 ng / ml apelin- Diluted and each treated for 1 hour. Then, in order to measure the secreted insulin amount, 1 ml of buffer treated in each cell was taken and the amount of insulin was measured by enzyme immunoassay.
As a result, it was confirmed that insulin secretion was slightly increased by apelin-16 as compared with the control group (2.5 mM glucose-treated group) (Fig. 1).
1-2: Insulin secretion in islets isolated from mouse
The collagenase P solution was injected into the common bile duct of the mouse (Central laboratory animal, Korea), and then the pancreas was removed. The extracted pancreas was reacted in a 37 ° C water bath for 13 minutes and 20 seconds, then filled with 5% FBS-HBSS and centrifuged to remove supernatant. The pellet was resuspended in cold FBS-HBSS, and then 6 ml of different gradients were mixed and centrifuged. Centrifuged, suspended in 10 ml of RPMI1640 medium, and inoculated into 100 mm culture dishes. Insulin secretion was measured in the same manner as in Example 1-1 with respect to the islets of the mice cultured separately.
The islets isolated from the mouse were washed twice with glucose-free KRBS buffer and diluted in KRBS buffer (pH 7.4) to give 2.5 mM glucose (negative control), 25 mM glucose (positive control) and 10 ng / ml Apelin-16 Was treated for 1 hour. Then, in order to measure the secreted insulin amount, 1 ml of buffer treated in each cell was taken and the amount of insulin was measured by enzyme immunoassay.
As a result, it was confirmed that apelin-16 increased insulin secretion as compared with the negative control group (2.5 mM glucose-treated group) and the positive control group (25 mM glucose-treated group) (Fig. 2).
Example 2: Insulin secretion induced by high concentration of glucose Apelin Check the effect of -16
In this example, pancreatic beta cell line (INS-1) was cultured in high glucose (25 mM glucose) to confirm insulin secretion by apelin-16 under high glucose concentration.
Insulin secretion was measured in the same manner as in Example 1-1 by treating the pancreatic beta cell line (INS-1) with 10 ng / ml Apelin-16 for 1 hour in each of 2.5 mM glucose condition and 25 mM glucose condition.
As a result, it was found that when apelin-16 was treated at 25 mM glucose condition, insulin secretion was significantly increased as compared with the case where apelin-16 was treated at 2.5 mM glucose (Fig. 3). In other words, the synergistic effect of apelin-16 was confirmed in the insulin secretion induced by high glucose concentration.
Example 3: Apelin -16 to inhibit fat accumulation
In this example, in order to confirm the effect of apelin-16 on obesity, apelin-16 was administered to abdominal cavity of obese-induced obesity-induced mouse, and blood test and fat accumulation in organ were observed . High-fat diet C57BL / 6 mice were reported to develop
Six weeks old C57BL / 6 mice were fed with a general diet for 2 weeks and fed 60% high fat diet for 12 weeks from 8 to 20 weeks of age. Ten rats were fed high-fat diets (HFD), while the remaining 10 rats were fed naproxen (ntra-peritoneal) for 12 weeks with aphelin-16 (0.5 μg / g / day) at the same time as the high fat diet (HFD). Twelve weeks old mice that had received 12 weeks of high fat diet and apelin administration were subjected to blood tests and laparotomy.
The results of blood tests showed that total cholesterol (CHO), glucose (GLU) and triglyceride (TG) levels increased in the high fat diet group compared to the control group, while total cholesterol (CHO), glucose GLU) and triglyceride (TG) levels were lower than those of the high fat diet group. In addition, insulin levels were increased in the group treated with apelin-16 compared to the high-fat group (Table 1). That is, it shows that the concentration of sugar is decreased by promoting insulin secretion by apelin-16.
Next, mice were observed to observe abdominal obesity and fatty liver due to accumulation of fat around the abdomen, epididymal, liver and kidney in the high fat diet group, and the group administered with apelin-16 It was confirmed that the accumulation of fat was suppressed in various organs (Fig. 4). In other words, apelin had an inhibitory effect on fat accumulation.
Example 4: Apelin -16 to confirm the effect on kidney damage
The effect of apelin-16 on diabetic complications, such as diabetic nephropathy, was confirmed by prolonged diabetes with damage to renal tissue and proteinuria due to hyperglycemia. High-fat diet of Example 3 Since C57BL / 6 mice are obese-induced hyperglycemic animal models, the effect on diabetic nephropathy was confirmed in the same experimental group.
Urinary albumin concentration (UAC) was measured one week before the sacrifice of 20 week old high-fat diet and apelin-treated 20-week-old mice in Example 3 by taking urine.
As a result, the albumin level in the urine of the mouse group induced by obesity was higher than that of the mouse (control group), whereas the albumin level in the urine of the mouse group treated with apelin-16 decreased to almost the same level as the control (Fig. 5). It can be seen that apelin-16 promotes insulin secretion and reduces the sugar level to some extent to prevent kidney damage caused by high concentrations of sugar.
Example 5: Comparison of various kinds of Apelin effect
To compare the increase in insulin secretion by various kinds of apelin, the present inventors measured the amount of insulin after depleting various kinds of apelin in islets isolated from pancreatic beta cell line (INS-1) and mouse.
5-1: Insulin secretion in pancreatic beta cell line (INS-1)
2 x 10 6 pancreatic beta cell lines (INS-1) were inoculated into 6-well plates and cultured in RPMI 1640 medium containing 6 mM glucose for 3 days. The cultured pancreatic beta cell line (INS-1) was washed twice with glucose-free KRBS buffer and then incubated with 2.5 mM glucose (negative control), 25 mM glucose (positive control) and 10 ng / ml Apelin- -12 were diluted in KRBS buffer and treated for 1 hour each. Then, in order to measure the secreted insulin amount, 1 ml of buffer treated in each cell was taken and the amount of insulin was measured by enzyme immunoassay.
As a result, it was confirmed that the insulin secretion was increased by apelin compared to the control group (2.5 mM glucose-treated group), and apelin-16 was found to have the best insulin secretion ability (Fig. 6). This means that the amino acid sequence between apelin-12 and apelin-16 is important for insulin secretory ability.
5-2: Insulin secretion in islets isolated from mouse
The collagenase P solution was injected into the common bile duct of the mouse and the pancreas was removed. The extracted pancreas was reacted in a 37 ° C water bath for 13 minutes and 20 seconds, then filled with 5% FBS-HBSS and centrifuged to remove supernatant. The pellet was resuspended in cold FBS-HBSS, and then 6 ml of different gradients were mixed and centrifuged. Centrifuged, suspended in 10 ml of RPMI1640 medium, and inoculated into 100 mm culture dishes. Insulin secretion was measured in the same manner as in Example 5-1 by using the islets of the thus separated and cultured mice.
The islets isolated from the mouse were washed twice with glucose-free KRBS buffer and then diluted with 2.5 mM glucose (negative control), 25 mM glucose (positive control) and 10 ng / ml Apelin-36, -16, Diluted in KRBS buffer and treated for 1 hour each. Then, in order to measure the secreted insulin amount, 1 ml of the buffer treated in each cell was taken and the amount of insulin was measured by enzyme immunoassay.
As a result, it was confirmed that the insulin secretion was increased by apelin compared to the negative control group (2.5 mM glucose treated group) and the positive control group (25 mM glucose treated group), and apelin-16 was relatively insulin secretory (Fig. 7). This means that the amino acid sequence between apelin-12 and apelin-16 is important for insulin secretory ability.
While the present invention has been particularly shown and described with reference to specific embodiments thereof, those skilled in the art will readily appreciate that many modifications are possible in the exemplary embodiments without materially departing from the novel teachings and advantages of this invention. something to do. Accordingly, the actual scope of the present invention will be defined by the appended claims and their equivalents.
Claims (12)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020150161139A KR101689803B1 (en) | 2015-11-17 | 2015-11-17 | Composition for preventing or treating of diabetes or obesity containing Apelin-16 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020150161139A KR101689803B1 (en) | 2015-11-17 | 2015-11-17 | Composition for preventing or treating of diabetes or obesity containing Apelin-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR101689803B1 true KR101689803B1 (en) | 2016-12-27 |
Family
ID=57737014
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020150161139A KR101689803B1 (en) | 2015-11-17 | 2015-11-17 | Composition for preventing or treating of diabetes or obesity containing Apelin-16 |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR101689803B1 (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20080045185A (en) * | 2005-08-11 | 2008-05-22 | 아밀린 파마슈티칼스, 인크. | Hybrid polypeptides with selectable properties |
| WO2009046824A2 (en) * | 2007-09-11 | 2009-04-16 | Mondobiotech Laboratories Ag | Use of a peptide as a therapeutic agent |
| CN104436158A (en) * | 2013-09-22 | 2015-03-25 | 华中科技大学 | Application of Apelin-13 to treatment of diabetic nephropathy |
-
2015
- 2015-11-17 KR KR1020150161139A patent/KR101689803B1/en active IP Right Grant
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20080045185A (en) * | 2005-08-11 | 2008-05-22 | 아밀린 파마슈티칼스, 인크. | Hybrid polypeptides with selectable properties |
| WO2009046824A2 (en) * | 2007-09-11 | 2009-04-16 | Mondobiotech Laboratories Ag | Use of a peptide as a therapeutic agent |
| CN104436158A (en) * | 2013-09-22 | 2015-03-25 | 华中科技大学 | Application of Apelin-13 to treatment of diabetic nephropathy |
Non-Patent Citations (1)
| Title |
|---|
| Peptides. Vol. 32, No. 8, pp. 1634-1639 (2011)* * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2878005A1 (en) | Composition and use of a formulation to increase the ratio of gastrointestinal microbiota in phylum bacteriodetes to microbiota of firmicutes phylum | |
| JP2011157345A (en) | Igf-1 secretion promoter | |
| KR20130029415A (en) | Composition for prevention, amelioration or treatment of metabolic syndrome | |
| KR101689803B1 (en) | Composition for preventing or treating of diabetes or obesity containing Apelin-16 | |
| KR101882492B1 (en) | Composition for appetite control containing ferulic aicd or pharmaceutically acceptable salts thereof as and active ingredient | |
| KR101713309B1 (en) | Food composition or pharmaceutical composition for immune activity with the extract of Pinus Koraiensis peel | |
| US20190231898A1 (en) | Pharmaceutical composition containing hyaluronic acid nanoparticles for preventing or treating inflammatory disease and metabolic disease | |
| US9801404B2 (en) | IGF-1 production-promoting agent | |
| JP2012082172A (en) | Dipeptidyl peptidase iv inhibitor containing schizandra chinensis water extract as active ingredient | |
| KR20210052360A (en) | Peptide for anti-obesity and use thereof | |
| KR101121954B1 (en) | Composition for preventing or treating diabetes comprising 1,2,3-Benzentricarboxylic acid | |
| US11324795B2 (en) | Composition comprising Hordeum vulgare extract for preventing or treating short stature | |
| KR101835997B1 (en) | Compositions comprising allyl sulfide compound for inhibition of gastric motility | |
| KR102335886B1 (en) | Composition for preventing or treating cardiometabolic syndrome comprising Elaeocarpus petiolatus | |
| KR20240033705A (en) | A composition for improving anti-obesity and fatty liver | |
| WO2022191184A1 (en) | Ghrelin receptor sensitivity-enhancing agent, ghrelin receptor sensitivity-enhancing composition, and ghrelin receptor activation method | |
| KR102115657B1 (en) | Composition for anti-obesity including geranic acid as an active ingredient | |
| US20140336220A1 (en) | Composition for preventing or treating obesity comprising rebamipide | |
| JP2021161070A (en) | Glp-1 secretion promoter | |
| US20210212959A1 (en) | Gip elevation inhibitor | |
| JP7044342B2 (en) | Pharmaceutical composition for diabetes prevention / treatment, food composition for blood sugar level improvement, and method for prevention / treatment of diabetes | |
| KR20240029547A (en) | Composition for improvement, prevention or treatment of muscular disorders, or improvement of muscular functions comprising quinic acid | |
| KR101768568B1 (en) | Composition for immunological engancement comprising sitosteryl ferulate | |
| WO2019168149A1 (en) | Peptide capable of improving cognitive function | |
| JP2016027042A (en) | GLP-1 production promoter, DPPIV inhibitor and glucose absorption inhibitor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant |